Weekly Fungal Diagnostics Update – June 15 2026

Posted on by

Key Points

  • Rapid molecular testing for Mucorales may help support earlier diagnosis of mucormycosis, a fast-moving and life-threatening fungal infection.
  • Polymerase chain reaction-based diagnostics may improve candidaemia management when linked to antifungal stewardship programmes.
  • Galactomannan testing of tracheobronchial aspirates may provide useful diagnostic information in lung transplant recipients at risk of Aspergillus infection.
  • New avian aspergillosis studies show how host-response biomarkers, proteomics, cell-free DNA analysis, Nanopore sequencing and machine learning may shape future fungal diagnostics.

Contents

Overall Summary

This week’s fungal diagnostics update highlights the growing importance of tests that can provide useful information quickly enough to influence clinical care.

Three papers are especially relevant to current practice: real-world Mucorales polymerase chain reaction testing for suspected mucormycosis, polymerase chain reaction-based antifungal stewardship for candidaemia, and galactomannan testing in tracheobronchial aspirates from lung transplant recipients.

Together, these studies show that faster fungal diagnostics are most useful when they are connected to clinical decision-making, treatment pathways, stewardship review and careful interpretation by specialist teams.

Two additional studies explored emerging diagnostic methods in avian aspergillosis. These are not directly applicable to human clinical practice, but they demonstrate how host-response biomarkers and advanced technologies may influence future fungal diagnosis.

Rapid Molecular Diagnosis of Mucormycosis

Paper: Haas AL, Hanson KE. Mucorales PCR for the rapid diagnosis of mucormycosis: 6 years of testing in a national reference laboratory and tertiary hospital. Journal of Clinical Microbiology. 2026.

Mucormycosis is a serious fungal infection caused by fungi from the order Mucorales. It can progress rapidly, particularly in people with weakened immune systems, uncontrolled diabetes, haematological disease, transplant-related immunosuppression or major tissue injury.

This study reports six years of experience using Mucorales polymerase chain reaction testing in a national reference laboratory and tertiary hospital setting. Molecular testing may help detect Mucorales DNA more rapidly than conventional approaches, which often depend on tissue sampling, microscopy, histopathology or culture.

Why this matters

Earlier diagnosis of mucormycosis can be critical because treatment decisions often need to be made quickly. Rapid polymerase chain reaction testing may help support earlier antifungal treatment, surgical planning and escalation of care when mucormycosis is suspected.

Clinical and diagnostic relevance

This is the most clinically actionable diagnostics paper in this week’s update. It supports the role of Mucorales polymerase chain reaction as part of a wider diagnostic pathway for suspected mucormycosis, especially when conventional tests are slow, insensitive or difficult to obtain.

Limitations and cautions

Polymerase chain reaction results should not be interpreted in isolation. Test performance may depend on sample type, fungal burden, timing of sampling, previous antifungal treatment and local laboratory validation. A negative result may not fully exclude mucormycosis if clinical suspicion remains high.

PCR-Guided Antifungal Stewardship in Candidaemia

Paper: Miyazaki K, Ishigo T, Yamada M, Takeda R, Wada N, Itaya M, Saijo M, Hoshi T, Saito Y. Effect of polymerase chain reaction-based antifungal stewardship on candidemia management in small- and medium-sized hospitals. Journal of Pharmaceutical Health Care and Sciences. 2026.

Candidaemia is a bloodstream infection caused by Candida species. It requires prompt recognition, appropriate antifungal treatment and attention to source control, including assessment of intravenous lines and other possible infection sources.

This study examined the effect of polymerase chain reaction-based fungal diagnostics as part of antifungal stewardship in small- and medium-sized hospitals. This setting is important because smaller hospitals may have less immediate access to specialist fungal infection services or advanced microbiology support.

Why this matters

Rapid diagnostics are most useful when results are acted upon. In candidaemia, faster organism identification can support earlier optimisation of antifungal treatment, review of catheter management, repeat blood culture planning and decisions about treatment duration.

Clinical and diagnostic relevance

The study is relevant to implementation because it links molecular testing to changes in clinical management. It supports a model in which diagnostics, pharmacy, microbiology and infectious diseases advice work together to improve antifungal use.

Limitations and cautions

The benefit of polymerase chain reaction-based stewardship may vary between hospitals. Local factors such as laboratory turnaround time, staffing, baseline candidaemia practice, availability of infectious diseases advice and adherence to care bundles will all influence impact. Polymerase chain reaction testing alone is unlikely to improve outcomes unless results are embedded in a clear stewardship pathway.

Galactomannan Testing in Lung Transplant Recipients

Paper: Monforte A, Martín-Gómez MT, Berastegui C, Márquez-Algaba E, Sacanell J, Rosado J, Falcó-Roget A, Escudero G, Casanovas J, Kirkegaard-Biosca C, Sáez-Giménez B, Monforte V, Gavaldà J, Len O, Los-Arcos I. Diagnostic value of galactomannan in tracheobronchial aspirate for Aspergillus infection in lung transplant recipients — the GALACTBAS study. Journal of Clinical Microbiology. 2026.

Lung transplant recipients are at increased risk of Aspergillus infection. Diagnosis can be difficult because Aspergillus detected in the airway may represent colonisation, tracheobronchitis or invasive disease.

The GALACTBAS study examined galactomannan testing in tracheobronchial aspirates. This sample type may be particularly relevant in lung transplant patients because Aspergillus disease can involve the bronchial tree early.

Why this matters

Clinicians need diagnostic tools that help interpret airway Aspergillus findings in high-risk transplant recipients. Tracheobronchial aspirate galactomannan may provide an additional diagnostic signal when used alongside bronchoscopy findings, imaging, culture, histology and clinical assessment.

Clinical and diagnostic relevance

This paper is directly relevant to transplant fungal diagnostics. It may support more nuanced use of respiratory galactomannan testing beyond serum and bronchoalveolar lavage fluid, particularly where airway-centred Aspergillus disease is suspected.

Limitations and cautions

A positive galactomannan result does not automatically prove invasive disease. Results must be interpreted in the full transplant context, including symptoms, imaging, airway appearances, microbiology and antifungal exposure. Diagnostic thresholds may not apply to other patient groups without further validation.

Emerging Host-Response and One Health Diagnostics

Two additional studies explored diagnostic innovation in avian aspergillosis. These are not currently human clinical tests, but they are useful examples of the wider move toward host-response biomarkers and data-rich diagnostic methods.

MethylSense: Cell-Free DNA Methylation and Nanopore Sequencing

Paper: Drag MH, Hvilsom C, Poulsen LL, Jensen HE, Tahas SA, Leineweber C, Cray C, Bertelsen MF, Bojesen AM. MethylSense: high accuracy machine learning-based diagnostics for Aspergillus fumigatus infection in chickens using host cell-free DNA methylation and Nanopore sequencing. Journal of Clinical Microbiology. 2026.

This study used host cell-free DNA methylation patterns, machine learning and Nanopore sequencing to detect Aspergillus fumigatus infection in chickens. Instead of relying only on direct detection of fungal material, the method appears to use the host response as part of the diagnostic signal.

The approach is innovative because it combines molecular data with computational classification. For human fungal disease, this type of method remains experimental, but it illustrates how future diagnostics may combine pathogen detection with host-response profiling.

Findings in chickens cannot be assumed to apply to people. Host methylation signatures are likely to be species-specific and may be affected by inflammation, age, co-infections and sampling conditions.

Falcon Plasma Proteomics

Paper: Vieu S, Lozano C, Azmanis P, Beaudeau F, Guillot J, Armengaud J. Falcon plasma proteomics to improve avian aspergillosis diagnosis. Journal of Proteomics. 2026.

This study investigated plasma proteomics as a way to improve diagnosis of aspergillosis in falcons. Avian aspergillosis can be difficult to diagnose early because symptoms may be non-specific and existing diagnostic tests have limitations.

Proteomics may help identify blood-based host-response patterns associated with fungal disease. Although this is a veterinary study, it reflects a broader trend toward biomarker panels that could eventually complement culture, imaging, antigen testing and molecular diagnostics.

The findings are not directly transferable to human aspergillosis. Proteomic biomarker discovery requires independent validation, standardised assays and evidence that the results improve clinical decisions.

What This Means for Fungal Diagnostics

This week’s papers show that fungal diagnostics are moving in two linked directions.

First, molecular and antigen-based tests are becoming more useful in immediate clinical pathways. Mucorales polymerase chain reaction may support earlier diagnosis of mucormycosis, polymerase chain reaction-based testing may strengthen candidaemia stewardship, and tracheobronchial aspirate galactomannan may improve interpretation of Aspergillus infection risk after lung transplantation.

Second, emerging research is moving toward host-response diagnostics. Cell-free DNA methylation, proteomics, Nanopore sequencing and machine learning are not yet routine tools for human aspergillosis care, but they show how future diagnostics may become more sensitive, earlier and more personalised.

Key message:
The most important development this week is not simply faster testing, but faster testing linked to action. Diagnostic results have the greatest value when they help clinicians make earlier, safer and more targeted treatment decisions.

When to Seek Medical Advice

This article is intended as a research update rather than personal medical guidance. People with symptoms of serious infection should seek urgent medical advice, especially if they have a weakened immune system, recent transplantation, cancer treatment, uncontrolled diabetes, severe lung disease or are taking immune-suppressing medication.

Symptoms that may require prompt medical assessment include fever, worsening breathlessness, chest pain, coughing blood, confusion, severe sinus or facial pain, blackened nasal tissue, persistent bloodstream infection, or rapid deterioration despite treatment.

References

  1. Haas AL, Hanson KE. Mucorales PCR for the rapid diagnosis of mucormycosis: 6 years of testing in a national reference laboratory and tertiary hospital. Journal of Clinical Microbiology. 2026.
  2. Miyazaki K, Ishigo T, Yamada M, et al. Effect of polymerase chain reaction-based antifungal stewardship on candidemia management in small- and medium-sized hospitals. Journal of Pharmaceutical Health Care and Sciences. 2026.
  3. Monforte A, Martín-Gómez MT, Berastegui C, et al. Diagnostic value of galactomannan in tracheobronchial aspirate for Aspergillus infection in lung transplant recipients — the GALACTBAS study. Journal of Clinical Microbiology. 2026.
  4. Drag MH, Hvilsom C, Poulsen LL, et al. MethylSense: high accuracy machine learning-based diagnostics for Aspergillus fumigatus infection in chickens using host cell-free DNA methylation and Nanopore sequencing. Journal of Clinical Microbiology. 2026.
  5. Vieu S, Lozano C, Azmanis P, et al. Falcon plasma proteomics to improve avian aspergillosis diagnosis. Journal of Proteomics. 2026.

Author: Graham Atherton, National Aspergillosis Centre (NAC)

Clinical Review: National Aspergillosis Centre Clinical Team

Last Reviewed: 15 June 2026

For Educational Purposes Only: This article is intended for educational and research update purposes and should not replace professional medical advice.